Genetic Technologies (STU:DU8) Total Stockholders Equity : €2.95 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genetic Technologies Total Stockholders Equity?

Genetic Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €2.95 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Genetic Technologies's Book Value per Share for the quarter that ended in Dec. 2023 was €0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Genetic Technologies's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.08.

Genetic Technologies Total Stockholders Equity Historical Data

The historical data trend for Genetic Technologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Total Stockholders Equity Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Stockholders Equity

Get a 7-Day Free Trial

1.09

8.58

13.66

10.92

6.92

Genetic Technologies Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															-	6.92	-	2.95	-

Genetic Technologies (STU:DU8) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Genetic Technologies's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(2.954	-	0)	/	115.417
	=	0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Genetic Technologies's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.183	+	0.052)	/	2.954
	=	0.08

Genetic Technologies Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (STU:DU8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

GENE:USA GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines